Degarelix Acetate Drug Asset Due Diligence Report 2026

This Degarelix Acetate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

152

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Degarelix Acetate can convert its Synthetic peptide profile and GnRHR biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Degarelix Acetate (query alias: degarelix)
Modality / target	Synthetic peptide; GnRHR; GnRHR antagonists
Highest global status	Approved
Originator	FERRING BV
Active developers	Ferring Arzneimittel Gmbh, Ferring Pharmaceuticals A/S, Accord Healthcare SL

The MCP disease footprint includes Castration-sensitive prostate cancer, Hormone-dependent prostate cancer, Prostatic Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07455903	Phase 2	Recruiting	50	Objective response rate (ORR) based on PSMA PET
NCT07335796	Phase 2	Recruiting	30	Frequency of pathologic complete response/pCR
ChiCTR2600121819	Not Applicable	Not yet recruiting	44	Progression-free survival

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase 2 Trial of Radium Ra 223 Dichloride in Combination With Androgen Deprivation Therapy and Stereotactic Body Radiation Therapy for Patients With Oligometastatic Castration Sensitive Prostate Cancer

Phase 2; n=25; evaluation: not stated. Reported fields: TTF(Median) = 17.0 months (95% Confidence Interval, 13.1 - 21.7); -; TTF(Median) = 42.1 months (95% Confidence Interval, 2.5 - NA)

Androgen deprivation, androgen receptor-targeted vaccination, and nivolumab in patients with high-risk localized prostate cancer

Phase 2; n=24; evaluation: Positive. Reported fields: MRD = 1.0 Pts ; -; -

Testosterone Recovery after Cessation of Luteinizing Hormone-Releasing Hormone Antagonists in Treatment of Prostate Cancer

Not Applicable; n=296; evaluation: Positive. Reported fields: Achieved testosterone recovery = 50.0 % ; Achieved testosterone recovery = 60.0 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Degarelix Acetate addresses Castration-sensitive prostate cancer, Hormone-dependent prostate cancer, Prostatic Cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Synthetic peptide—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2021-08-13	辉瑞与辉凌就前列腺癌创新药注射用醋酸地加瑞克达成战略合作，携手满足中国患者治疗需求	Approved	Financial terms not disclosed
2006-01-31	Ferring and Astellas enter a license agreement on Degarelix for the treatment of prostate cancer in Japan	Phase 3	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO